• Wed. Feb 8th, 2023

Recap: Biomarin Pharmaceutical Q3 Earnings – Biomarin Pharmaceutical (NASDAQ:BMRN)

ByBenzinga Insights

Oct 26, 2022
Recap: Biomarin Pharmaceutical Q3 Earnings - Biomarin Pharmaceutical (NASDAQ:BMRN)

Biomarin Pharmaceutical BMRN reported its Q3 earnings results on Wednesday, October 26, 2022 at 04:00 PM.

Here’s what investors need to know about the announcement.

Earnings

Biomarin Pharmaceutical missed estimated earnings by 300.0%, reporting an EPS of $-0.04 versus an estimate of $-0.01.

Revenue was up $96.60 million from the same period last year.

Past Earnings Performance

Last quarter the company beat on EPS by $0.48 which was followed by a 5.18% increase in the share price the next day.

Here’s a look at Biomarin Pharmaceutical’s past performance:








Quarter Q2 2022 Q1 2022 Q4 2021 Q3 2021
EPS Estimate 0.11

-0.32 -0.25
EPS Actual 0.59 0.17 -0.32 -0.20
Revenue Estimate 521.47M 507.52M 442.39M 435.32M
Revenue Actual 533.80M 519.36M 449.81M 408.74M








Quarter Q2 2022 Q1 2022 Q4 2021 Q3 2021
EPS Estimate 0.11

-0.32 -0.25
EPS Actual 0.59 0.17 -0.32 -0.20
Revenue Estimate 521.47M 507.52M 442.39M 435.32M
Revenue Actual 533.80M 519.36M 449.81M 408.74M

To track all earnings releases for Biomarin Pharmaceutical visit their earnings calendar here.

This article was generated by Benzinga’s automated content engine and reviewed by an editor.



Image and article originally from www.benzinga.com. Read the original article here.